Mentis Cura November
|
|
|
- Holly Barnett
- 5 years ago
- Views:
Transcription
1 Mentis Cura November
2 New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s million millon 2
3 Soaring Costs 18 th largest economy in the world Costs to rise by 80% by 2030 Will cripple healthcare 70% of cost occurs in Western Europe and North America Call for early detection and biomarkers Alz. Association 10 year call for biomarker development UK Chief Medical Officer calling for early detection Economical diagnosis needed 3
4 EEG as the biomarker, 1 st line of defense:// EEG measures electrical charges which are disrupted from onset of disease. More data showing disease developing earlier, years before clinical symptoms New data on relationship with sleep apnea & lifestyle factors 4
5 Other biomarkers & diagnostics Mainly used to rule out other disease and are not able do diagnose dementia until in later stages CT and MRI Volumetric loss: secondary changes to decrease in synaptic density, neuronal loss, and cell shrinkage fmri Functional MRI: detects abnormal (secondary) changes in cerebral blood flow with contrast 5
6 Other biomarkers & diagnostics PET (Positron Emission Tomography) Relevant in the study of dementia, no clinical use Measures cerebral glucose metabolic rate SPECT (Single-Photon Emission Computed Tomography Measures blood flow in certain regions of the brain Spinal Fluid Invasive and risky. No standards acknowledged Not specific to dementia 6
7 Stages of Dementia 7
8 Mentis Cura Biomarker 8
9 Building the Dementiagram EEG Recording Generate Multidementional Classifier Extract features -Classical Spectral features; d,q,a,b, and g bands. Coherences in same frequency range -A total of features are extracted from each EEG recording Generate Index Classifiers are generated for each possible pair of groups in the EEG database to make a differential analysis possible. There are a total of 10 classifers pairs included in the Mentis Cura Dementiagram As a result of this, the system generates 2 indices for each classifier in the dementiagram, i.e. for the Dementiagram which includes NRM, MCI, DPR, AD, & L-P 20 indeces are generated. The Mentis Cura Dementiagram This process is repeated ten times for the Dementiagram 9
10 Mentis Cura Report Differential Diagnosis Mild Cognitive Impairment Depression Alzheimer s Disease Lewy Body Parkinson Dementia Automatic Statements Easy interpretation of DementiaGram Cholinergic Index Baseline Monitor progression Treatment effect Dose response 10
11 11
12 EEG Cholinergic Index A biomarker measuring activity of the Cholinergic system Monitor disease progression of dementia Monitor treatment efficacy of cholinesterase inhibitors Monitor during titration / dose response
13 Background Leading medications indicated for treatment of mild AD are cholinesterase inhibitors. The effects of the medicines are measured by cognitive tests and by caregiver reports without the support of biomarkers. Physicians face the challenge of choosing from a wide range of dozes. With the recent FDA Approval of high dose formulations of Rivastigmine and Donepezil, the difference between low and high doze is more than fourfould! Rivastigmine is available in and 13.3mg Donepezil is available in 5 10 and 23mg A theoretically possible method is to measure the cholinergic response to these drugs in the brain. It has been proposed that the EEG changes seen in AD are primarily a reflection of cholinergic dysfunction. We suggest that by establishing a "cholinergic index" in EEG registration, the treatment effects of cholinergic drugs could be measured and thereby the treatment response. 13
14 Developing the Index In a clinical trial, 38 healthy elderly participants participated an EEG registration Recordings were obtained from each participant before and after a 5 mg sc administration of scopolamine. Since scopolamine affects the cholinergic neurotransmitter system, a cholinergic EEG index was created by applying Statistical Pattern Recognition (SPR) to a large set of EEG features, by considering the group before and after scopolamine administration as two distinct groups. The resulting classifier results in an index that correlates with the cholinergic activity in the subject. The EEG cholinergic index calculated for 38 individuals before (blue) and after (red) 5 mg scopolamine sc injection. The second EEG recording took place 2.5 hours after injection. 14
15 Control vs AD The EEG Cholinergic Index calculated for 317 healthy elderly individuals and 583 AD individuals. Groups are distinctively different 15
16 Mentis Cura Cholinergic Index Correlation to cognitive measure: MMSE MMSE The EEG Cholinergic Index calculated for 317 healthy elderly individuals and 620 individuals with dementia. Correlates to Mini Mental State Examination (MMSE) Alzheimer s Dementia with Lewy bodies Parkinson s Disease Dementia Vascular Dementia Mild Cognitive Impairment Depression leading to dementia symptoms Pearson s Linear Correlation : 0.56±0.02 (Evaluated by Bootstrap) 16
17 Mentis Cura Cholinergic Index Correlation to cognitive measure: DSST DSST score The EEG Cholinergic Index calculated for 317 healthy elderly individuals and 374 individuals with dementia. Correlates to Digital Symbol Substitution Test (DSST) Alzheimer s Dementia with Lewy bodies Parkinson s Disease Dementia Vascular Dementia Mild Cognitive Impairment Depression leading to dementia symptoms Pearson s Linear Correlation : 0.59±0.02 (Evaluated by Bootstrap) 17
18 Post operative cognitive function following coronary artery bypass grafting (CABG) 18
19 CABG/ Overview Around 1 million CABG surgeries are conducted annually worldwide Due to advance in surgical medicine CABG surgeries are now being conducted on older individuals than before and on individuals with comorbid diseases such as hypertension and diabetes. This has lead to increased awareness of the many serious and life threatening neurological difficulties associated with CABG surgeries. Stroke and postoperative delirium are well known and studied difficulties following CABG with incidence rates around 3% and up to 9 % in those older than 75 years of age. Post Operative Cognitive Deficits (POCD) and depression following CABG have gained increased interest in recent years. Studies have shown incidence rates of POCD from 33-83% and around 25% for depression. Findings on POCD are conflicting and there is great need for further studies 19
20 Study Design Trial period: Started in 2010 on-going. Estimated population size: 30 individuals who have undergone CABG surgery at the Landspitali University Hospital in Iceland. Purpose: An informative study using EEG as neurophysiologic parameters to reflect the effect of CABG on depression, anxiety and cognition of patients Procedure: Following measures will be conducted at baseline (at least one week before surgery) and postoperative at 3-5 months and at one year follow up: Questioners assessing depression (BDI) and anxiety (BAI) Neuropsychological assessment measuring memory, motor speed, executive function and visuospatial abilities EEG with a protocol of 5 min. resting eyes closed, 5 min eyes open/closed. Additional data: Clinical data such as physical parameters will be gathered from the Department of Surgery and Cardiothoracic Surgery clinical database. 20
21 Mentis Cura Cholinergic Index Change 12 months after operation CABG Ach EEG Index results Postoperative improvement Postoperative impairment Mentis Cura Cholinergic Index before operation Correlation : Subjects Subjects with low cholinergic activity benefit from operation Subjects with cholinergic activity within normal range show postoperative impairment Change evident 12 months postoperatively
22 Mentis Cura Cholinergic Index Change 3-4 months after operation CABG Ach EEG Index results Postoperative improvement Postoperative impairment Mentis Cura Cholinergic Index before operation Correlation : Subjects Subjects with low cholinergic activity benefit from operation Subjects with cholinergic activity within normal range show postoperative impairment Change evident 3-4 months postoperatively. Not as clear as after 12 months.
23 Monitoring Cholinesterase Inhibitor treatment in Alzheimer s patients 23
24 Monitor Treatment Efficacy A longitudinal study with 42 AD patients over 12 months (4 visits) was performed. The Cholinergic Index was calculated for each participant at each visit. The initial EEG recording takes place before treatment for AD is initiated. A week later treatment for AD starts. Results from a longitudinal trial. The average EEG Cholinergic Index is calculated for 42 AD individuals over a 12 month period. The average MMSE score for the same individuals is shown for comparison. The first point is calculated before treatment for AD is initiated. Two months after treatment with acetylcholinesterase inhibitors began the Cholinergic Index rose by almost 19 points. 24
25 Responders and non-responders Integrated treatment response for 42 AD patients over the course of one year as evaluated by the EEG Cholinergic Index. The individuals are classified as responders (positive overall response) or non-responders (negative overall response). 25
26 The EEG Cholinergic Index correlates significantly with MMSE, with a coefficiant of 0,42 This suggests that the EEG Cholinergic Index can be used to: a) Monitor cholinergic activity at the patient level establish a baseline or a reference point b) Monitor treatment response c) Monitor dose response d) Monitor disease progression 26
27 The EEG Cholinergic Index A biomarker for Cholingergic activity and dementia Non-invasive Affordable Readily available Provides relevant information Suitable for research Monitor patients in the clinical environment The EEG Cholinergic Index is a part of the Mentis Cura Dementia Analysis software. The index is based on a standardized EEG recordings. The user can upload any EEG file in an EDF file format and receive the dementia report within minutes 27
28 Mentis Cura Environment Stakeholders Distributors & Equipment Manufacturers Physicians & Service Providers Researchers & Academic Institutions Payers Pharmaceuticals Mentis Cura Patients 28
29 Mentis Cura Contribution Aligned with key stakeholders Researchers & Academic Institutions Exploit database potential Novel ways of researching brain function Publications Distributors & Equipment Manufacturers Increase sales of existing product line Service existing customers by fuelling growth Physicians & Service Providers Opening new market segments Better servicing customers demanding better service Payers Saving money on Diagnostics Non-responders Pharmaceuticals Save $ during trials Increase chance of success Validate who should receive treatment Validate dosing Mentis Cura Patients Diagnostic improvement Treatment monitoring 29
30 Distributors & Equipment Manufacturers Physicians & Service Providers Researchers & Academic Institutions Payers Pharmaceuticals Mentis Cura Patients 30
31 Stockholm Brain Institute One of World s leading brain research centers External Partnership Agreement by January Major recognition of Mentis Cura work Partnership to focus on monitoring the following: Dementia Diagnostics Clinical Trials and Research Analysing Existing Data Monitoring of cognitive decline in trauma, post surgery etc ADHD 31
Fact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
Detection of Mild Cognitive Impairment using Image Differences and Clinical Features
Detection of Mild Cognitive Impairment using Image Differences and Clinical Features L I N L I S C H O O L O F C O M P U T I N G C L E M S O N U N I V E R S I T Y Copyright notice Many of the images in
BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER
OVERCOMING THE CHALLENGES OF MANAGING CHRONIC DISEASES IN PERSONS WITH DEMENTIA DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER LEARNING OBJECTIVES Be familiar with the diagnostic criteria for
Diagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
BGS Spring Risk Factors and Preventative Strategies for Dementia
Risk Factors and Preventative Strategies for Dementia Dr Blossom Stephan Senior Lecturer (in Risk Prediction) Newcastle University Institute for Ageing and Institute of Health and Society BGS Spring Meeting
They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
diagnosis and assessment bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
Dementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
Subject Index. Berkson bias 72
Subject Index AAAT study 62 Absolute risk reduction (ARR) 40 ACCORD study 62 AD, see Alzheimer s disease ADVANCE study 62 ALLHAT study 62 ALS, see Amyotrophic lateral sclerosis Alzheimer s disease (AD)
Dementia: It s Not Always Alzheimer s
Dementia: It s Not Always Alzheimer s A Caregiver s Perspective Diane E. Vance, Ph.D. Mid-America Institute on Aging and Wellness 2017 My Background Caregiver for my husband who had Lewy Body Dementia
Erin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
Vascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
Mild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
Clinical Trial Glossary
Clinical Trial Glossary Adverse event An unfavorable change in health that can occur during a clinical trial or study or within a certain time period after. These can range from mild (e.g., nausea) to
BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
Pocket Reference to Alzheimer s Disease Management
Pocket Reference to Alzheimer s Disease Management Pocket Reference to Alzheimer s Disease Management Anna Burke, MD Geriatric Psychiatrist, Dementia Specialist Geri R Hall, PhD, ARNP, GCNS, FAAN Advanced
Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:
Alzheimer s Disease A Public Health Response July 19, 2007 1 2 Guest Speakers Thanks to our Sponsors: Earl A. Zimmerman, M.D. Bender Endowed Chair of Neurology and Director of the Alzheimer s Center at
Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia
Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia Case Study Mr. S. is a 74 year old man who has smoked for 20 years. He is overweight, has high cholesterol and high
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
An Objective Assessment of Psychological Injuries in the 21 st Century
An Objective Assessment of Psychological Injuries in the 21 st Century Professor Cherrie Galletly Discipline of Psychiatry, University of Adelaide Professor Alexander C. McFarlane The Centre of Military
Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
Understanding Dementia
Understanding Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor, Department of Psychiatry, Queen s University, Kingston, Ontario, Canada What s Next Information about Dementia, Elder Care and Supports
Northeast Center for Special Care Grant Avenue Lake Katrine, NY
300 Grant Avenue Lake Katrine, NY 12449 845-336-3500 Information Bulletin What is Brain Mapping? By Victor Zelek, Ph.D., Director of Neuropsychological Services Diplomate, National Registry of Neurofeedback
Neuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
The IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases
The IAEA and Non-Communicable Diseases The Fight Against Non-Communicable Diseases The International Atomic Energy Agency works to improve human health through the use of nuclear techniques. This includes
Neuroimaging and Neurostimulation: Going inside the black box
Neuroimaging and Neurostimulation: Going inside the black box Benzi M. Kluger M.D., M.S. Director, Movement Disorders Center Associate Professor of Neurology & Psychiatry University of Colorado OUTLINE
Molecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
Analysis of the U.S. Medical Computed Tomography Imaging Systems Market
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the U.S. Medical Computed Tomography Imaging Systems Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market
PROJECTION: Worlds dementia population is expected to triple by 2050
DEMENTIA C L I S K C O N S U LTA N T P H Y S I C I A N I N A C U T E M E D I C I N E A N D G E R I AT R I C M E D I C I N E, B A R N E T H O S P I TA L, R O YA L F R E E N H S F O U N D AT I O N T R U
GLOBAL NEUROSTIMULATION MARKET
GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d
Alzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
Carotid Artery Reactivity Measurement among Healthy Young People towards Early Detection of Alzheimer Disease
Carotid Artery Reactivity Measurement among Healthy Young People towards Early Detection of Alzheimer Disease MOHD AMINUDIN JAMLOS, EKO SUPRIYANTO Department of Clinical Science and Engineering Faculty
Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities ( )
Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities (2012-17) Scope of the Report The report titled Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17) provides
Moving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
Imaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
For personal use only
ASX Announcement Melbourne, 29 July 2011 CogState CogState (ASX:CGS) today provided further details of its financial results for the year ended 30 June 2011 along with an update in respect of progress
Novartis: tackling adherence. ESPACOMP, September, 2010
Novartis: tackling adherence ESPACOMP, September, 2010 Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by market capitalization Among most respected companies
COGNITIVE SCIENCE 17. Peeking Inside The Head. Part 1. Jaime A. Pineda, Ph.D.
COGNITIVE SCIENCE 17 Peeking Inside The Head Part 1 Jaime A. Pineda, Ph.D. Imaging The Living Brain! Computed Tomography (CT)! Magnetic Resonance Imaging (MRI)! Positron Emission Tomography (PET)! Functional
Speech perception in individuals with dementia of the Alzheimer s type (DAT) Mitchell S. Sommers Department of Psychology Washington University
Speech perception in individuals with dementia of the Alzheimer s type (DAT) Mitchell S. Sommers Department of Psychology Washington University Overview Goals of studying speech perception in individuals
Research and possible future brain health treatments
Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1 The Roskamp Institute Not for profit biomedical research
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
Noninvasive cardiac imaging refers
CARDIOLOGY PATIENT PAGE Introduction to Noninvasive Cardiac Imaging Ron Blankstein, MD Noninvasive cardiac imaging refers to a combination of methods that can be used to obtain images related to the structure
The Nervous System. Biological School. Neuroanatomy. How does a Neuron fire? Acetylcholine (ACH) TYPES OF NEUROTRANSMITTERS
Biological School The Nervous System It is all about the body!!!! It starts with an individual nerve cell called a NEURON. Synapse Neuroanatomy Neurotransmitters (chemicals held in terminal buttons that
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
2006 Annual Report. Anastomosis Made Simple
2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,
"Active Mind" Programme Helps Approximately 10,000 Senior Citizens Prevent Dementia
1 2 J u l y 2 0 1 0 "Active Mind" Programme Helps Approximately 10,000 Senior Citizens Prevent Dementia 55% of elderly population suspected to be suffering from memory problems or dementia In Hong Kong,
INSERT COMPANY LOGO HERE
2013 2014 INSERT COMPANY LOGO HERE 2014 North American 2013 North Positron American Emission SSL Tomography Certificate (PET) Imaging Technology Product Innovation Leadership Leadership Award Award Industry
Electrophysiologic approaches to delirium. Overview
Electrophysiologic approaches to delirium Alvaro Pascual Leone, MD, PhD Mouhsin Shafi, MD, PhD Overview Overview of the problem and techniques Electrophysiological studies in delirium Electrophysiological
Index SLEEP MEDICINE CLINICS. Note: Page numbers of article titles are in boldface type.
299 SLEEP MEDICINE CLINICS Sleep Med Clin 1 (2006) 299 303 Note: Page numbers of article titles are in boldface type. A Acid reflux, sleep disturbances in older adults related to, 238 Aging, alterations
A U. Methods of Cognitive Neuroscience 2/8/2016. Neat Stuff! Cognitive Psychology
Methods of Cognitive Neuroscience Neat Stuff! Optogenetics http://spie.org/newsroom/technical-articles-archive/videos/0411-boyden Stimulating the brain with light Cognitive Psychology Mental Representation
Appendix K: Evidence review flow charts
K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What
Outline. Biological Psychology: Research Methods. Dr. Katherine Mickley Steinmetz
Biological Psychology: Research Methods Dr. Katherine Mickley Steinmetz Outline Neuroscience Methods Histology Electrophysiological Recordings Lesion Neuroimaging Neuroanatomy Histology: Brain structure
Assessing cognition in ELDERLY drivers
Assessing cognition in ELDERLY s Alexandra Economou Assistant Professor Department of Psychology University of Athens 18 October 2013 Athens Overview ability in the older ability in the older The older
An Introduction to Neuroscience. A presentation by Group 3
An Introduction to Neuroscience A presentation by Group 3 Neuroscience Overview Neuroscience is one of the largest growing fields of science today. Works with many other fields: chemistry, biology, engineering,
David A Scott Lis Evered. Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne
David A Scott Lis Evered Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne This talk will include live polling so please be sure to have the meeting
IT S ALL ABOUT EVIDENCE
IT S ALL ABOUT EVIDENCE COVERAGE WITH EVIDENCE DEVELOPMENT IN CANADA DEVIDAS MENON, SCHOOL OF PUBLIC HEALTH, UNIVERSITY OF ALBERTA 2012 CADTH SYMPOSIUM, Ottawa, 17 April 2012 What s this all about? Experience
Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
CHAPTER 17: HEALTH PSYCHOLOGY CHAPTER 18: NEUROPSYCHOLOGY
OUTLINE CHAPTER 17: HEALTH PSYCHOLOGY Role of Health Psychologists Stress & Illness Pain Management CHAPTER 18: NEUROPSYCHOLOGY Brain trauma Disorders of brain atrophy Neuro-assessment Professor Fazakas-DeHoog
After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs
PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET
PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask Presented By: Alexander I. Tröster, PhD, ABPP University of North Carolina, Chapel Hill, NC Tuesday, March
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
CHAPTER 15: NEUROCOGNITIVE DISORDERS KEY TERMS. Acetylcholine A neurotransmitter that appears to be involved in learning and memory.
CHAPTER 15: NEUROCOGNITIVE DISORDERS KEY TERMS Acetylcholine A neurotransmitter that appears to be involved in learning and memory. Adult Memory and Information Processing Battery (AMIPB) A neuropsychological
Methods for Seeing the Brain (http://www.pbs.org/wnet/brain/scanning/)
Mind-Brain There are 2 broad approaches to connecting brain and cognitive activity: 1. (modern) Imaging techniques 2. (classic) Patients with brain trauma H. Jackson, A.R. Luria, O. Sacks Methods for Seeing
PRESS NOTES YORK INSTRUMENTS Last updated 2018
PRESS NOTES YORK INSTRUMENTS Last updated 2018 York Instruments: Company Profile York Instruments is a medical technology company set to radically transform the field of functional brain imaging. The company
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
QiG INS Conference May 22, 2011
Strategy & Vision Growth Electrochem Medical Device Evolution QiG Cardio vascular QiG INS Conference May 22, 2011 Greatbatch Medical Neuro modulation 1 GREATBATCH TODAY 2010 Revenue by Product Line NYSE:
Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia
Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia ADI 2018, Chicago FACULTY OF MEDICINE Dr Emily Reeve NHMRC Cognitive Decline
Parkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
Dementia and Delirium: A Neurologist s Approach to Altered Mental Status. Case 1 4/7/11. Which of the following evaluations is your next step?
Dementia and Delirium: A Neurologist s Approach to Altered Mental Status S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University of California San Francisco
Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
MOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
CHANGES AT A GLANCE. WHAT S NEW AND DIFFERENT? SEPTEMBER 2017.
CHANGES AT A GLANCE. WHAT S NEW AND DIFFERENT? SEPTEMBER 2017. Enhancements to CommInsure Protection: Income Protection more IP cover options to suit your circumstances Introducing Income Care Platinum,
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
Gastrocnemius, see Medial gastrocnemius Glucose, see Blood glucose
Subject Index Acute myocardial infarction, see Myocardial infarction Aerobic capacity cardiac patients and Tai Chi training effects 185 heart failure and Tai Chi outcomes 198 200, 202, 205 meta-analysis
Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
View Report Details. Global Coronary Stent Market
View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more
Term Paper: Ginkgo Biloba s Influence on Memory and Cognition
1 Term Paper: Ginkgo Biloba s Influence on Memory and Cognition 2 Introduction The aging process is inevitable. Over time our bodies and the functions they provide start to decline in many aspects. Cognitive
Stroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013
Stroke 101 Maine Cardiovascular Health Summit Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013 Stroke Statistics Definition of stroke Risk factors Warning signs Treatment
Alzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
Rev (10/2014) VMA: A New Standard in Spine Diagnostic Imaging
Rev. 1038-1.1 (10/2014) VMA: A New Standard in Spine Diagnostic Imaging Spine Surgeons Lack Reliable Function Tests Critical to Other Surgeons Functional Tests Used to Select Surgery Patients Non-Specific
Cognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle
Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:
Brain Resource. For personal use only. riding the wave of demand for brain health solutions
Brain Resource riding the wave of demand for brain health solutions Dan Segal, COO dans@brainresource.com Sydney and San Francisco May 2011 1 10 year track record Founded 2001, international research consortium
Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
The evox System. A medical device to measure and train the brain evox System
The A medical device to measure and train the brain 1-800-957-5520 What Is evox? The medical device to MEASURE & TRAIN brain function. Measure clinically-proven biomarkers Objectively track treatment success